Identification, validation and commercial development of new diagnostic and prognostic biomarkers for complex diseases.
Biomarkers are essential tools for early diagnosis, to identify the phase of a disease and to assess treatment effectiveness.
The IVASCOMAR project focuses on identifying, validating and commercially developing both diagnostic and prognostic biomarkers for Alzheimer and Parkinson diseases, multiple sclerosis and diabetes, all chronic, high incidence and high social cost diseases.
The synergy created by the various players involved generated a sort of “research industry” where research bodies and universities produce a pipeline of molecules that are then validated as biomarkers by companies.
The process is expected to produce intellectual property that can translate into prognostic and diagnostic tools to be sold on the biotechnological and pharmaceutical markets or used to create start-ups.
An important part of the project is to train highly specialized professional figures in the biotechnological and pharmaceutical sectors, with specific economic and business management skills.
Project Leader: Dompè
Partners: Sentinel, Primm, Colosseum Combinatorial Chemistry Centre for Technology, Università degli Studi di Milano-Bicocca, Università Vita-Salute San Raffaele, Fondazione Centro San Raffaele
Project Manager: Giancarlo Comi (San Raffaele)
Accounting Manager: Daniele Zacchetti (San Raffaele)
Training Manager: Fabio Grohovaz (San Raffaele)